What is the Association Between PSA Levels and the Severity of Coronary Artery Disease in Patients with and without Myocardial Infarction?

Mehrdad Habashizadeh, Davood Kazemi Saleh, Zahra Pourjafar, Razieh Rezaei and Mahdi Karbaschi

Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

Keywords: Coronary artery disease; Prostate specific antigen; Angiography

Introduction

Currently, cardiovascular diseases are the most common causes of death in the world and Iran and constitute 40% of all deaths [1]. By 2020 the most important estimated cause of mortality and morbidity in developing countries will be coronary artery disease [2-4]. Each year, an average 90000 cardiovascular-related deaths occur in Iran [5]. The roles of risk factors such as diabetes, hypertension, dyslipidemia and cigarette smoking in cardiovascular diseases are well-known. At the time being, insulin resistance and type 2 diabetes are on the rise and are considered powerful risk factors for IHD [6,7].

Studies conducted in recent years have referred to the association between prostate specific antigen (PSA) and cardiovascular diseases. Moreover, the cardiogenic shock following acute myocardial infarction and coronary artery bypass grafting (CABG) in CAD patients was associated with an increase in PSA [8].

CABG has been associated with serum PSA and benign prostatic hyperplasia (BPH), where patients with high PSA levels are more likely to have CAD than those with low levels of PSA [9].

To date, an association between PSA levels and the severity of coronary artery involvement and major cardiovascular accidents has been reported [10]. However, the numbers of studies conducted in this regard are not many, and have yielded different results; hence it seemed necessary to conduct a study with a larger sample size.

Determining the risk of heart disease has been a significant issue and researchers have always attempted to find new cost-effective and non-invasive techniques. Therefore, the purpose of this study was to find an association between PSA levels and the severity of coronary artery involvement in patients with and without acute myocardial infarction. If an association is found, PSA can be used as another indicator for CAD and also for predicting the severity of coronary artery involvement before angiography.

Methods

A cross-sectional study was conducted on patients requiring angiography in Tehran's Baqiyatallah Hospital's Angiography Department during the April-September 2014 period. The samples were selected non-randomly on the basis of certain inclusion/exclusion criteria. Inclusion criteria: all patients who had undergone angiography during the April-September 2014 period. Exclusion criteria were: patients with a history of angiography and/or previous angioplasty, CABG, history of BPH, prostatitis, prostaticectomy, prostatic biopsy and prostate cancer. In this study we examined 200 men who underwent coronary angiography; 100 with acute myocardial infarction (MI) and 100 suspected to have CAD (without myocardial infarction). Using statistical formula for Comparison two independent populations and previous studies14, we reached to sample size equally
200 patients. Patients with acute MI were further classified into two groups, those with STEMI and those with NSTEMI. The patients were classified into two groups. The first group comprised those who had attended the emergency department and who had been diagnosed with acute MI and who had subsequently undergone angiography. The second group consisted of suspicious to have CAD patients who were on elective angiography. Before angiography Total PSA and Free PSA were measured in all patients. All blood samples were sent to a reference lab where the Electrochemoluminescence (ECLIA) technique was applied.

The Gensini score is a scoring system in which the type and severity of the coronary artery involvement-based on the percentage of lumen narrowing-are used to set a score for each patient.

In this study an obstruction greater than 50% of the coronary vessel diameter was considered significant. Based on the type and number of coronary vessels involved in coronary angiography, the patients were classified into the following groups: 3 vessels, 2 vessels, 1 vessel, non-obstructive and normal. Obstructions of 1VD, 2VD and 3VD refer to the numbers of vessels involved with a narrowing greater than 50%. The non-obstructive group refers to the group that had smaller than 50% obstruction. All the angiographies were interpreted by two cardiologists.

By severity of coronary artery involvement we are referring to two variables, the Gensini score (severity of coronary vessel involvement) and the number of coronary vessels involved. By prostate specific antigen we are referring to the Total PSA, Free PSA and Free/Total PSA variables.

After completing the data they were entered into the SPSS 20 software. Quantitative variables such as mean and standard error of mean (SEM) were used and the Kruskal-Wallis test was used to compare the quantitative variables because the variables were not normal distribution (with the Kolmogorov-Smirnov test). To analyse and determine the association between numerical variables Correlation Coefficient was applied. A p value<0.05 was considered significant.

### Table 1: Relation between PSA indices with MI (STEMI, NSTEMI) and suspicious to have CAD.

Data regarding the patients’ age, history of cigarette smoking, hypertension, hyperlipidemia, diabetes and familial history of CAD were gathered. The consent form was completed by all the participants and they were ensured of the confidentiality of their data.

| Variables                      | STEMI (n=29) | P-Value | NSTEMI (n=71) | P-Value | Suspicious to have CAD (n=100) | P-Value |
|-------------------------------|-------------|---------|---------------|---------|-------------------------------|---------|
| Free PSA (mean ± SEM)         | r=0.315     | P=0.096 | r=0.24        | P=0.043 | r=0.23                        | P=0.021 |
| Total PSA (mean ± SEM)        | r=0.403     | P=0.030 | r=0.19        | P=0.081 | r=0.22                        | P=0.024 |
| Free/Total PSA (mean ± SEM)   | r=-0.164    | P=0.397 | r=0.21        | P=0.081 | r=0.08                        | P=0.411 |

### Table 2: Relation between PSA indices with Gensini score in STEMI, NSTEMI and suspicious to have CAD groups.

| Variables                      | STEMI (n=29) | P-Value | NSTEMI (n=71) | P-Value | Suspicious to have CAD (n=100) | P-Value |
|-------------------------------|-------------|---------|---------------|---------|-------------------------------|---------|
| Free PSA                      | r=0.080     | 0.679   | r=-0.103      | 0.408   | r=0.151                       | 0.177   |
| Total PSA                     | r=0.128     | 0.508   | r=-0.212      | 0.076   | r=0.077                       | 0.451   |
| Free/Total PSA                | r=-0.171    | 0.377   | r=0.215       | 0.08    | r=0.066                       | 0.556   |

### Table 3: Correlation between PSA indices level and STEMI, STEMEDI and suspicious to have CAD groups.

| Variables                      | Coefficient β | P     |
|-------------------------------|---------------|-------|

### Results

The mean age of the participants was 64 ±11. Patients with acute MI were those with STEMI (14.5%); those with NSTEMI (35.5%) and others suspicious to have CAD (50%). Coronary angiography results were normal in 1.5%, non-obstructive CAD in 15%, one-vessel disease in 23%, two-vessel disease in 31% and three-vessel disease in 30%.

According to the diversity and severity of patients with coronary artery disease in this survey and some high levels of Gensini score in samples, the distribution of this variable was not normal.

Table 1 shows the relation of Free PSA, Total PSA and Free/Total PSA ratio for each of the STEMI and NSTEMI and suspicious to have CAD (without myocardial infarction) groups respectively.

Table 2 shows the relation of Free PSA, Total PSA and Free/Total PSA ratio with Gensini score for each of the STEMI and NSTEMI and suspicious to have CAD (without myocardial infarction) groups respectively.

Table 3 shows the relation of Free PSA, Total PSA and Free/Total PSA ratio with Coronary Angiography (Number of coronary vessels involved) for each of the STEMI and NSTEMI and suspicious to have CAD (without myocardial infarction) groups respectively.

Multivariate regression analysis for GENSINI score; including Age, Free PSA, Total PSA, Free/TotalPSA revealed significant correlation with Free PSA and Total PSA (Table 4).
This test for coronary artery disorders is also important. Moreover, determining the sensitivity, specificity and predictive value of an association between coronary heart disease and PSA in patients undergoing coronary angiography, both those who had an MI and those who were suspected to have CAD. We found a moderate correlation and significant association between Total PSA and the Gensini coefficient in only STEMI patients. We may interpret this as such, that the greater involvement of the coronary vessels, the higher the PSA level, and vice versa. Patanè's 2009 study results were similar to ours in the sense that patients with acute MI had higher Total and Free PSA levels [8]. Weisman's results were very similar to ours, such that a high level of PSA in men with BPH was associated with the frequency of CAD [9,10].

Another research conducted by Patane et al. in 2012 showed a significant relationship between PSA levels and NSTEMI [13]. However, Satiroglu’s study states otherwise, and has reported no correlation and significant association between increased PSA levels and coronary vessel involvement, and hence concluded that an elevated PSA level is not a suitable indicator for diagnosing or predicting the severity of CAD [14]. However, to our knowledge, no cohort or case-control study has been conducted on the prognosis of cardiovascular disease and PSA levels, and hence further studies of higher evidence are required.

PSA may be used as a predictor for coronary vessel involvement. However, determining the sensitivity, specificity and predictive value of this test for coronary artery disorders is also important. Moreover, the level of scientific evidence is low in cross-sectional studies; hence cohort or case-control studies should be conducted.

Table 4: Multivariate regression analysis for GENSINI score; including age, Free PSA, Total PSA, Free/Total PSA.

|           | Coefficient | p-value |
|-----------|-------------|---------|
| Age       | 0.019       | 0.804   |
| Free/Total PSA | 0.024 | 0.791   |
| Free PSA  | 0.221       | 0.013   |
| Total PSA | 0.44        | 0.009   |

Discussion

Cardiovascular diseases are the most common causes of death in the world, and many risk factors such as diabetes, hypertension, dyslipidemia and cigarette smoking have been identified in its etiology [6,7].

Therefore, in this study we investigated the effect of an association between coronary heart disease and PSA in patients undergoing coronary angiography, both those who had an MI and those who were suspected to have CAD. We found a moderate correlation and significant association between Total PSA and the Gensini coefficient in only STEMI patients. We may interpret this as such, that the greater involvement of the coronary vessels, the higher the PSA level, and vice versa. Patanè's 2009 study results were similar to ours in the sense that patients with acute MI had higher Total and Free PSA levels [8]. Weisman's results were very similar to ours, such that a high level of PSA in men with BPH was associated with the frequency of CAD [9,10].

Tahir Durmaz also found an average correlation and significant association between the Gensini coefficient and Free PSA and Free/Total PSA [11]. Boroumand et al studied 151 patients in Iran in 2011 and observed significantly higher PSA levels in patients with high Gensini scores [12].

Another research conducted by Patane et al. in 2012 showed a significant relationship between PSA levels and NSTEMI [13]. However, Satiroglu's study states otherwise, and has reported no correlation and significant association between increased PSA levels and coronary vessel involvement, and hence concluded that an elevated PSA level is not a suitable indicator for diagnosing or predicting the severity of CAD [14]. However, to our knowledge, no cohort or case-control study has been conducted on the prognosis of cardiovascular disease and PSA levels, and hence further studies of higher evidence are required.

PSA may be used as a predictor for coronary vessel involvement. However, determining the sensitivity, specificity and predictive value of this test for coronary artery disorders is also important. Moreover, the level of scientific evidence is low in cross-sectional studies; hence cohort or case-control studies should be conducted.

Acknowledgments

We would like to thank all those who helped conduct this study, particularly Baqiyatallah Hospital’s Emergency and Angiography Departments’ staff. Last but not least, we are grateful to all the patients who participated in the study.

References

1. Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349: 1436-1442.
2. The World Health Report (1999) The double burden: Emerging epidemics and persistent problems. WHO.
3. Howson CP, Reddy KS, Ryan TJ, Bale JR (1999) Control of cardiovascular diseases in developing countries - Research, development and institutional strengthening. HeartBeat: Bulletin of the World Heart Federation.
4. Murray CJ, Lopez AD (1996) The global burden of disease. In: Murray CJ, Lopez AD (eds.) The global burden of disease: a comprehensive assessment of mortality and disability from disease, injuries and risk factors in 1990 and projected to 2020. Harvard School of Health, Boston.
5. Sadeghpour E, Khosrovani M (1381) Risk factors threatening health in Iran and around the world. In: A Comprehensive Textbook on Public Health. Arjmand Publications, Tehran.
6. Antam ME, Selwyn AP, Lospalzo (2012) Ischemic heart disease. In: Lango DL (eds.) Harrison’s principles of medicine (18thedn.) McGrow Hill, Health Profession Division, New York, pp. 1998-2015.
7. Scott MG, Gary JB, Michael HC (1998) Primary prevention of coronary heart disease: Guidance from Framingham. Circulation 97: 1876-1887.
8. Patanè S, Marte F (2009) Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system. Eur Heart J 30: 1169-1170.
9. Weisman KM, Larijani GE, Goldstein MR, Goldberg ME (2000) The relationship between benign prostatic hyperplasia and history of coronary artery disease in elderly men. Pharmacotherapy 20: 383-386.
10. Patanè S, Marte F, Sturiale M, Grassi R, Patanè F (2010) Significant coronary artery disease associated with coronary artery aneurysm and elevation of prostate-specific antigen during acute myocardial infarction. Int J Cardiol 141: e39-e42.
11. Durmaz T, Ayhan H, Keles T, Bilen E, Akcay M, et al. (2014) Is there a Relationship Between Acute Coronary Syndrome and Prostate Specific Antigen Levels? Urology journal 11: 1278-1286.
12. Boroumand MA, Anvari MS, Amelimjoordar E, Shoar S, Naderan M, et al. (2011) Association between angiographically assessed coronary artery disease and serum levels of prostate specific antigen. Clin Lab 57: 975-981.
13. Patanè S, Marte F (2012) Prostate-specific antigen levels in hypertensive patients suffering from a non-ST elevation myocardial infarction or a new-onset atrial fibrillation. Int J Cardiol 158: 380-382.
14. Satiroglu O, Bostan M, Uzun H, Cetin M, Bozkurt E (2012) Severity of coronary artery disease and prostate-specific antigen relationship in men. Eur Rev Med Pharmacol Sci 16: 2078-2081.